Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 1/2 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4NETWORK 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Thoracic 1CNS 1

Conditions

Prostatic Neoplasms 2Ovarian Neoplasms 2SCLC,Extensive Stage 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × niraparib × 30 days × Clear all
NCT05523440 2026-06-03

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

University of Oklahoma

Phase 2 Terminated
9 enrolled 10 charts
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT04992013 2026-06-01

Niraparib in Tumors Metastatic to the CNS

Massachusetts General Hospital

Phase 2 Active not recruiting
20 enrolled
CNS

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT05718323 2026-05-29

RAISE

ETOP IBCSG Partners Foundation

Phase 2 Recruiting
44 enrolled
Thoracic

SCLC,Extensive Stage

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT04030559 2026-05-14

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

University of California, Davis

Phase 2 Terminated
11 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡